Anti-proliferative effects of new staurosporine derivatives isolated from a marine ascidian and its predatory flatworm

被引:34
作者
Schupp, P [1 ]
Steube, K
Meyer, C
Proksch, P
机构
[1] Univ New S Wales, Ctr Marine Biofouling & Bioinnovat, Sydney, NSW 2052, Australia
[2] Deutsch Sammlung Mikroorganismen & Zellkulturen G, D-38124 Braunschweig, Germany
[3] Inst Pharmazeut Biol, D-40225 Dusseldorf, Germany
关键词
anticancer drug; human leukemia cell lines; inhibition of cell proliferation; staurosporines; structure activity relationships;
D O I
10.1016/S0304-3835(01)00694-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nine indolocarbazole alkaloids of the staurosporine. type, including three new derivatives, were evaluated for their potential as inhibitors of cell proliferation and macromolecule synthesis. Four derivatives were tested as inhibitors of cell proliferation with twelve human leukemia cell lines and demonstrated powerful antiproliferative activities, with 3-hydroxystaurosporine being the most potent. IC50 values were determined using the cell line MONO-MAC-6 and with an IC50 of 13 ng/ml, 3-hydroxystaurosporine turned out to be one of the most active staurosporine-type inhibitors described so far. All derivatives, except 3-hydroxy-3'-demethoxy-3'-hydroxystaurosporine and 4'-N-methylstaurosporine very strongly reduced RNA and DNA synthesis with 3-hydroxystaurosporine again being the strongest inhibitor. Analysis of structure-activity relationships demonstrated that hydroxylation of staurosporine at position 3 of the indolocarbazole moiety caused an increase in anti-proliferative activity, while hydroxylation at carbon 11 resulted in a decrease in activity. Our results suggest that not only the presence or absence of hydrophilic substitutions, but also the position of the alteration within the molecule, is important in the antiproliferative properties of the various staurosporine analogues. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 46 条
[1]   ENHANCEMENT OF ANTITUMOR-ACTIVITY OF MITOMYCIN-C INVITRO AND INVIVO BY UCN-01, A SELECTIVE INHIBITOR OF PROTEIN-KINASE-C [J].
AKINAGA, S ;
NOMURA, K ;
GOMI, K ;
OKABE, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (03) :183-189
[2]   Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2 cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole [J].
Akiyama, T ;
Shimizu, M ;
Okabe, W ;
Tamaoki, T ;
Akinaga, S .
ANTI-CANCER DRUGS, 1999, 10 (01) :67-78
[3]   Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin [J].
Anizon, F ;
Moreau, P ;
Sancelme, M ;
Voldoire, A ;
Prudhomme, M ;
Ollier, M ;
Severe, D ;
Riou, JF ;
Bailly, C ;
Fabbro, D ;
Meyer, T ;
Aubertin, AM .
BIOORGANIC & MEDICINAL CHEMISTRY, 1998, 6 (09) :1597-1604
[4]   Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation [J].
Beltran, PJ ;
Fan, D ;
Fidler, IJ ;
OBrian, CA .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (02) :245-247
[5]   INDUCTION OF A COMMON PATHWAY OF APOPTOSIS BY STAUROSPORINE [J].
BERTRAND, R ;
SOLARY, E ;
OCONNOR, P ;
KOHN, KW ;
POMMIER, Y .
EXPERIMENTAL CELL RESEARCH, 1994, 211 (02) :314-321
[6]  
Bohnenstengel FI, 1999, Z NATURFORSCH C, V54, P1075
[7]   Characterization of the cell death process induced by staurosporine in human neuroblastoma cell lines [J].
Boix, J ;
Llecha, N ;
Yuste, VJ ;
Comella, JX .
NEUROPHARMACOLOGY, 1997, 36 (06) :811-821
[8]   A new staurosporine analog from the prosobranch mollusk Coriocella nigra [J].
Cantrell, CL ;
Groweiss, A ;
Gustafson, KR ;
Boyd, MR .
NATURAL PRODUCT LETTERS, 1999, 14 (01) :39-46
[9]   Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells [J].
Courage, C ;
Snowden, R ;
Gescher, A .
BRITISH JOURNAL OF CANCER, 1996, 74 (08) :1199-1205
[10]   COMPARISON OF ABILITY OF PROTEIN-KINASE-C INHIBITORS TO ARREST CELL-GROWTH AND TO ALTER CELLULAR PROTEIN-KINASE-C LOCALIZATION [J].
COURAGE, C ;
BUDWORTH, J ;
GESCHER, A .
BRITISH JOURNAL OF CANCER, 1995, 71 (04) :697-704